Cipla Sustainability
Sustainability
Our approach to responsible resource consumption, efforts to enhance access and affordability of medicines worldwide and strong financial growth, provide a robust foundation to build a responsible business.
8% Revenue CAGR over the last 5years
5.2% R&D Investment
₹ 21,763 Crores Revenue from Operations
Manufacturing Highlights
Our investments in manufacturing capital include development of new drug delivery systems, facilitation of infrastructure supporting API and formulation developments and strengthening of platform technologies.
32.72 Billion
Tablets and capsules
144.20 Million
Aerosol pMDI
11.45 Million
Lyophilised injections
750 Million
Repsules
50.60 Million
Nasal sprays
51.20 Million
Oral liquids
2.50 Million
Form-fill seal eye-drops
COMMITTEES
OF BOARD
Learn MoreOF BOARD
MILESTONE
AWARDS
Learn MoreAWARDS
